The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results. AstraZeneca and Eli Lilly’s lanabecestat showed it was unlikely to meet primary endpoints during clinical trials, accord...
Original Article: AstraZeneca and Lilly’s Alzheimer’s drug fails trial